Stable formulations comprising thiotepa

By adding PEG, DMSO and water to the Sedipel preparation and combining antioxidants to form a stable composition, the problem of Sedipel in aqueous solution is solved, and the stability and efficiency of long-term storage and use are achieved.

CN119053320APending Publication Date: 2024-11-29SHORLA PHARMA LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380034274.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-16
Filing Date
2023-02-15
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Sedipel is unstable in aqueous solutions, resulting in degradation of impurities and active ingredients during storage, making it difficult to store and use.

Method used

Using a composition containing sedipi, PEG or DMSO and water, by adding appropriate solvents and antioxidants, a stable anhydrous or aqueous composition is formed to avoid impurities and remain stable during storage.

Benefits of technology

It realizes the long-term stability of the Sedipel preparation and is suitable as a ready-to-use liquid dosage-forming drug product. It can be stored for one month to six months under room temperature or refrigeration conditions, improving the service life and efficiency of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005085262420000033
    Figure BDA0005085262420000033
  • Figure BDA0005085262420000071
    Figure BDA0005085262420000071
  • Figure BDA0005085262420000081
    Figure BDA0005085262420000081
Patent Text Reader

Abstract

The present disclosure provides a pharmaceutical composition comprising thiotepa, water, one selected from PEG (e.g., PEG400 or PEG600) and DMSO, and optionally, a thiosulfate salt / ester, or such a composition that is free or substantially free of impurities. Also provided are methods of treating cancer in a subject using the compositions or performing bone marrow cell clearance prior to bone marrow transplantation. Also contemplated are methods for enhancing the stability of a thiotepa formulation.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 310,638, filed on February 16, 2022. The entire disclosure of the application designated in this paragraph is incorporated herein by reference. Technical Field

[0002] The present disclosure relates to compositions comprising thiotepa and methods of using the compositions to treat a disease in a subject. Background Art

[0003] Thiotepa is a nitrogen mustard alkylating agent with anti-tumor properties. It is indicated for the treatment of adenocarcinoma of the breast, superficial papillary carcinoma of the bladder, and blood disorders in adults and children (such as Hodgkin's disease or leukemia). Thiotepa is also indicated for the control of intracavitary effusions secondary to diffuse or localized neoplastic disease in the serous cavity. Thiotepa is also used as conditioning therapy prior to allogeneic or autologous hematopoietic progenitor cell transplantation, or for palliation of neoplastic disease.

[0004] Thiotepa is generally unstable in aqueous solutions, which results in the generation of impurities and / or thiotepa degradation products upon storage. Aqueous instability makes ready-to-use liquid dosage forms of thiotepa difficult to store.

[0005] It is generally available as an excipient-free lyophilized product (15 mg to 100 mg) that is reconstituted in sterile water for injection to a concentration of 10 mg / mL. When given intravenously, thiotepa is given as a 2-4 hour infusion in a dose range of 3.24-14 mg / kg / day for a cumulative dose of 1050 mg / m 2 (42 mg / kg) to treat solid tumors.

[0006] US2014 / 0005148 describes non-aqueous formulations of nitrogen mustards, including thiotepa. Nitrogen mustards are susceptible to nucleophilic attack by water and other aqueous solvents (such as ethanol), which degrade the nitrogen mustards into degradation products.

[0007] EP 0 419 890 reports on lyophilized and anhydrous thiotepa compositions comprising polyethylene glycol (PEG). This reference reports that thiotepa reconstituted in water should be used within 5 days, as reconstituted thiotepa stored for more than 5 days shows a substantial loss of potency.

[0008] US2020 / 0163979 describes a pharmaceutically acceptable injectable liquid formulation containing thiotepa, which contains at least one solvent or co-solvent, such as ethanol. It is reported that after storage for 7 days at 25°C / 60% relative humidity, the composition containing ethanol has a purity of at least 90% thiotepa. Summary of the invention

[0009] This section provides a general summary of the disclosure, and is not a comprehensive disclosure of its full scope or its features.

[0010] The present disclosure relates to a composition comprising thiotepa, PEG or DMSO and water. In an embodiment, the composition is free of impurities or substantially free of impurities. The composition of the present disclosure is stable and may be suitable for injection. In an embodiment, the thiotepa formulation can be used to treat a disease (particularly cancer) or myeloablation before a bone marrow transplant.

[0011] In an embodiment, the thiotepa composition comprises PEG, such as PEG 400 or PEG 600. In another embodiment, the composition comprises DMSO.

[0012] In an alternative embodiment, the composition is an anhydrous composition comprising thiotepa and a solvent, such as DMSO, PEG400, PEG600, DMA and NMP, wherein the composition is free or substantially free of impurities.

[0013] In an embodiment, the composition further comprises a thiosulfate.

[0014] In an embodiment, a method for treating cancer in a subject is provided, the method comprising administering by injection a composition comprising thiotepa, PEG or DMSO, and water. In another embodiment, the PEG is PEG400 or PEG600. In a specific embodiment, the composition administered further comprises thiosulfate.

[0015] In another embodiment, a method for myeloablation of a subject prior to bone marrow transplantation is provided, the method comprising administering the thiotepa composition.

[0016] In another embodiment, a method for enhancing the stability of a thiotepa formulation is provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.

[0018] Figure 1 The chromatogram of the thiotepa composition of Example 1 is shown. Specific instructions

[0019] The following description is merely exemplary and is not intended to limit the present disclosure, application, or uses.

[0020] The term "thiotepa" refers to the compound N,N',N"-triethylenethiophosphoramide and is also known as or is known by the product name. Unless otherwise specified, thiotepa includes the compound itself and pharmaceutically acceptable salts thereof.

[0021] The term "non-aqueous" refers to a composition (eg, a solution, liquid, or suspension) that contains no water or substantially no water.

[0022] The term "subject" refers to an animal to which a thiotepa composition can be administered. In some embodiments, the subject is a human. In a specific embodiment, the subject has or is believed to have cancer. In another embodiment, the subject requires myeloablation or lymphodepletion prior to a bone marrow transplant or other therapy requiring a conditioning regimen. In another embodiment, the subject requires gene therapy.

[0023] The term "cancer" includes, but is not exclusive of, bladder cancer, malignant meningeal neoplasms, breast cancer, ovarian cancer, hematological malignancies, lymphoma, brain metastases, and meningeal metastases.

[0024] The term "injection" refers to a method of administration in which the composition is administered into the body through a needle. In an embodiment, the injection is selected from the group consisting of subcutaneous injection, intramuscular injection, intravenous injection, infusion, intraperitoneal injection, intrapleural injection, intrapericardial injection, intrathecal injection, intraarterial injection, intravesical injection and intralesional injection. The injection can be a single injection, including acute injection or continuous injection. The injection can be completed within a few days.

[0025] The term "substantially free" refers to the amount of a component that is not intended to be present in the composition but may still be present due to the manufacturing process and / or post-manufacturing degradation products. As used herein, the compositions described below may be substantially free of impurities, including, but not limited to, formic acid, acetic acid, formaldehyde, acetaldehyde, and peroxides. In some embodiments, when the composition is processed and / or refined beyond what is conventional in the art, it may be substantially free of impurities. For example, PEG400 may undergo additional processing and / or refining and may be referred to as "super refined", such as the Super Refined PEG400 provided by Croda Health Care. TM PEG400 and EMPROVE provided by Sigma TM PEG.

[0026] In some embodiments, when the impurity is present in the composition in an amount less than about 100 ppm, the composition is substantially free of impurities. In other embodiments, the composition substantially free of impurities comprises impurities in an amount less than about 95 ppm, less than about 90 ppm, less than about 85 ppm, less than about 80 ppm, less than about 75 ppm, less than about 70 ppm, less than about 65 ppm, less than about 60 ppm, less than about 55 ppm, less than about 50 ppm, less than about 45 ppm, less than about 40 ppm, less than about 35 ppm, less than about 30 ppm, less than about 25 ppm, less than about 20 ppm, less than about 15 ppm, less than about 10 ppm, less than about 5 ppm, or less than about 1 ppm. Alternatively, the amount of impurities in the composition can be expressed as a range, such as between about 1 ppm to about 100 ppm, between about 1 ppm to about 95 ppm, between about 1 ppm to about 80 ppm, between about 1 ppm to about 75 ppm, between about 1 ppm to about 70 ppm, between about 1 ppm to about 65 ppm, between about 1 ppm to about 60 ppm, between about 1 ppm to about 55 ppm, between about 1 ppm to about 50 ppm, between about 1 ppm to about 45 ppm, between about 1 ppm to about 40 ppm, between about 1 ppm to about 35 ppm, between about 1 ppm to about 30 ppm, between about 1 ppm to about 25 ppm, between about 1 ppm to about 20 ppm, between about 1 ppm to about 15 ppm, between about 1 ppm to about 10 ppm, between about 1 ppm to about 5 ppm, or between about 1 ppm to about 3 ppm.

[0027] When the concentration of a component is described as a percentage of the composition, the composition is substantially free of impurities. In this manner, a composition substantially free of impurities may contain less than about 0.0001%, less than about 0.000095%, less than about 0.00009%, less than about 0.000085%, less than about 0.00008%, less than about 0.000075%, less than about 0.00007%, less than about 0.000065%, less than about 0.00006%, less than about 0.000055%. , less than about 0.00005%, less than about 0.000045%, less than about 0.00004%, less than about 0.000035%, less than about 0.00003%, less than about 0.000025%, less than about 0.00002%, less than about 0.000015%, less than about 0.00001%, less than about 0.000005% or less than about 0.000001% impurities. Alternatively, the amount of impurities in the composition can be expressed as a percentage range, for example, between about 0.000001% and about 0.0001%, between about 0.000001% and about 0.000095%, between about 0.000001% and about 0.00009%, between about 0.000001% and about 0.000085%, between about 0.000001% and about 0.00008%, between about 0.000001% and about 0.000075%, between about 0.000001% and about 0.00007%, between about 0.000001% and about 0.000065%, between about 0.000001% and about 0.00006%, between about 0.000001% and about 0.000075 ... Between about 0.000055%, between about 0.000001% and about 0.00005%, between about 0.000001% and about 0.000045%, between about 0.000001% and about 0.00004%, between about 0.000001% and about 0.000035%, between about 0.000001% and about 0.00003%, between about 0.000001% and about 0.000025%, between about 0.000001% and about 0.00002%, between about 0.000001% and about 0.000015%, between about 0.000001% and about 0.00001%, or between 0.000001% and 0.000005.

[0028] The term "impurity" refers to substances other than the ingredients specifically specified and included in the composition of the present disclosure. In some embodiments, the impurity is one or more selected from the group consisting of formic acid, acetic acid, formaldehyde, acetaldehyde and peroxide.

[0029] The term "peroxide value" refers to the concentration of hydroperoxides, which are molecules (e.g., H2O2) with a peroxide (-OOH) moiety. Peroxide value is usually measured in milliequivalents of active O2 per kilogram of fatty substance (mEq O2 / kg fat). Composition

[0030] The present disclosure provides a composition comprising thiotepa or its derivatives (e.g., metabolites) and one or more excipients. Such compositions include pharmaceutical compositions containing thiotepa, PEG or DMSO, and water. Thiotepa is the active ingredient of the preparation, and its amount can be adjusted as needed. In general, all known / approved thiotepa amounts can be used with the preparation. In an embodiment, thiotepa is present in an amount of about 1 to about 100 mg / mL. In another embodiment, thiotepa is present in an amount of about 5 to about 50 mg. In a specific embodiment, thiotepa is present at a concentration of about 10 mg / mL.

[0031] In an embodiment, the amount of water present can be up to about 40% by weight. In another embodiment, by weight, water is present in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 20%, about 25% or about 30%. In a specific embodiment, water is present in an amount of about 10% by weight. In some embodiments, water is distilled water, purified water or ultrapure water. In another embodiment, water can include saline or phosphate buffer to prepare isotonic solution.

[0032] The compositions described herein are free of or substantially free of impurities, including but not limited to formic acid, acetic acid, formaldehyde, acetaldehyde, and peroxide. The compositions may contain impurities in an amount of less than about 35ppm, less than about 30ppm, less than about 25ppm, less than about 20ppm, less than about 15ppm, less than about 10ppm, less than about 5ppm, or less than about 1ppm. Alternatively, impurities may be present in a range of about 1 to about 35ppm, about 1 to about 30ppm, about 1 to about 25ppm, about 1 to about 20ppm, about 1 to about 15ppm, about 1 to about 10ppm, about 1 to about 5ppm, or about 1 to about 3ppm.

[0033] The compositions described herein may have a peroxide value of less than about 2.0, less than about 1.5, less than about 1.0, less than about 0.5, or less than about 0.1. In a specific embodiment, when the excipient is PEG400, the peroxide value is less than about 1.0, preferably less than about 0.5.

[0034] When there is more than one impurity (two or more in formic acid, acetic acid, formaldehyde, acetaldehyde and peroxide), the composition can be substantially free of one or more in every kind of impurity.For example, the composition can be substantially free of formic acid, but is not substantially free of peroxide.In addition, when there are two or more impurities, it can be considered that the overall composition is substantially free of every kind of impurity existing at different levels.For example, the composition can include the formic acid that is less than about 15ppm, the acetic acid that is less than 15ppm, the formaldehyde that is less than 15ppm, the acetaldehyde that is less than 15ppm, the peroxide that is less than 35ppm, or its combination.In another example, the composition can include the formic acid that is less than about 15ppm, the acetic acid that is less than 15ppm, the formaldehyde that is less than 15ppm, the acetaldehyde that is less than 15ppm and the peroxide that is less than 35ppm that the impurity is respectively less than about 15ppm.

[0035] In an embodiment, the composition comprises PEG in an amount between about 80% and about 100%. In another embodiment, the PEG can be a PEG between PEG200 and PEG400. In a specific embodiment, the PEG is selected from PEG400 and PEG600. In a specific embodiment, the composition comprises Super Refined TM PEG400 or EMPROVE TM PEG.

[0036] In alternative embodiments, the composition comprises dimethyl sulfoxide (DMSO) in an amount between about 90% to about 100%.

[0037] In another embodiment, the thiotepa composition further comprises one or more antioxidants. In some embodiments, antioxidants include ascorbic acid, tocopherol, methionine (such as L-methionine), pyrosulfite, propyl gallate, butylated hydroxyanasole, butylated hydroxytoluene, meglumine, thiosulfate. More preferred antioxidants are propyl gallate, thiosulfate (preferably sodium thiosulfate) and tocopherol (preferably α-tocopherol, more preferably α-tocopherol-PEG-succinate). Α-Tocopherol-PEG-succinate is a commercially available conjugate of α-tocopherol and PEG1000, which has high solubility in a short PEG manner. The most preferred antioxidants are thiosulfate (preferably sodium thiosulfate) and tocopherol (preferably α-tocopherol, more preferably α-tocopherol-PEG-succinate). In a preferred embodiment, a composition according to the present invention is provided, the composition further comprising an antioxidant (such as thiosulfate, propyl gallate or tocopherol). In a more preferred embodiment, a composition according to the present invention is provided, the composition further comprising an antioxidant selected from thiosulfate and / or tocopherol. In a most preferred embodiment, a composition according to the present invention is provided, the composition further comprising an antioxidant selected from sodium thiosulfate and / or alpha-tocopherol (preferably alpha-tocopherol-PEG-succinate).

[0038] In specific embodiments, the antioxidant (such as thiosulfate) is present in an amount between about 0.01% to about 1.0% by weight. In other embodiments, the thiosulfate is present in an amount of about 0.1% by weight.

[0039] The thiotepa composition may further comprise additional excipients, and non-limiting examples of such excipients include buffers, antioxidants, and / or osmotic agents.

[0040] In a specific embodiment, the composition comprises about 1 to about 100 mg / mL thiotepa, PEG or DMSO, and up to about 20% water by weight. If PEG is used, the PEG can be PEG400 or PEG600. The composition may also contain thiosulfate. Specific examples of thiotepa compositions are exemplified in Table 1.

[0041] Table 1: Thiotepa-containing formulations

[0042] In another embodiment, the thiotepa composition is in the form of a solution, suspension or liquid. In yet another embodiment, the thiotepa composition is an aqueous solution. In some embodiments, the composition is in the form of a parenteral formulation suitable for injection.

[0043] In an optional embodiment, thiotepa is formulated with an anhydrous composition. In an embodiment, the anhydrous thiotepa composition comprises thiotepa and a solvent selected from the group consisting of DMSO, PEG400, PEG600, dimethayacetamide (DMA) and n-methyl-2-pyrrolidone (NMP). In another embodiment, the anhydrous thiotepa composition further comprises an antioxidant (such as tocopherol) and / or an organic base (such as Tris base). In a specific embodiment, the thiotepa composition comprises about 1 to about 100 mg / mL thiotepa and DMSO, PEG400, PEG600, DMA or NMP. The specific embodiments of the anhydrous thiotepa composition are shown in Table 2.

[0044] Table 2: Formulations containing anhydrous thiotepa

[0045] Specific compositions that are substantially free of impurities are shown in Table 3 below.

[0046] Table 3: Thiotepa-containing formulations substantially free of impurities

[0047] Among other things, the composition of the present disclosure is intended to solve the stability problem of thiotepa in aqueous solution. It is known that thiotepa has stability problems in aqueous solution, such as the generation of impurities and degradation of active ingredients during storage. Aqueous instability makes the ready-to-use liquid dosage form of thiotepa difficult to store. The stable thiotepa composition of the present disclosure is suitable for ready-to-use liquid dosage form drug products. In an embodiment, the thiotepa composition is stable in the dark for one month, two months, three months or longer at room temperature (e.g., 21°C-25°C) or refrigeration (e.g., 4°C-5°C). In another embodiment, thiotepa is stable for up to six months at room temperature (50% relative humidity) or refrigeration. In a specific embodiment, the thiotepa composition is stored for a period of time, such as 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years or 3 years. Treatment

[0048] The present disclosure provides various methods for treating diseases (such as cancer) using the thiotepa composition. In an embodiment, the thiotepa composition is administered to a subject to treat cancer, wherein the subject needs such treatment. A variety of cancers can be treated by the composition, and in some embodiments, the cancer is selected from the group consisting of bladder cancer, malignant meningeal neoplasms, breast cancer, and ovarian cancer. In some other specific embodiments, the method is used to treat breast adenocarcinoma, control intracavitary effusions of diffuse or localized neoplastic diseases secondary to various serous cavities, and / or treat superficial papillary carcinoma of the bladder. In an embodiment, the composition is used in combination with one or more chemotherapeutic agents for adult and pediatric subjects with blood diseases (such as Hodgkin's disease and leukemia).

[0049] The thiotepa composition is administered to provide a therapeutically effective dose to achieve one or more therapeutic objectives. In some embodiments, the therapeutically effective amount is sufficient to treat cancer. In a specific embodiment, the therapeutically effective amount is between about 300 mg and about 700 mg. If a patient requires more than 850 mg of thiotepa, the drug may be used twice or more in one day. In another embodiment, the therapeutically effective amount of thiotepa is between about 4 and about 20 mg / kg body weight. In an optional embodiment, the therapeutically effective amount is between about 120 and about 300 mg / m 2 Thiotepa may be administered on one day over the course of multiple days, such as over the course of 1 to 5 days, in particular over the course of 1 to 2 days.

[0050] The thiotepa composition therapy can be combined with various cancer treatments known in the art. In an embodiment, the thiotepa composition is administered to a subject together with radiotherapy. In another embodiment, the thiotepa composition is administered before, after, or simultaneously with another chemotherapeutic agent. For the treatment of breast cancer or ovarian cancer, the therapeutically effective dose may be between about 20 mg and about 40 mg, administered every 1 to 4 weeks.

[0051] In some embodiments, a therapeutically effective amount of thiotepa is administered prior to a bone marrow transplant to induce bone marrow cell clearance. In a specific embodiment, the therapeutically effective amount of thiotepa is between 300 mg / mL and 700 mg / mL. In another embodiment, a therapeutically effective amount of thiotepa for bone marrow cell clearance prior to a bone marrow transplant is provided within 1 to 5 days or 1 to 2 days. The total amount of thiotepa delivered during the treatment of bone marrow cell clearance prior to a bone marrow transplant may be about 850 mg or more. Ways to increase stability

[0052] In an embodiment, a method for enhancing the stability of a thiotepa formulation is provided. In an embodiment, the method comprises the steps of combining thiotepa, water, and an excipient, wherein the excipient is PEG or DMSO; and homogenizing the combination. In some embodiments, the thiotepa concentration of the homogenized formulation is between about 1 and about 100 mg / mL. In some embodiments, water accounts for between about 1% and about 20% of the composition by weight. In a specific embodiment, thiotepa is present at about 10 mg / mL and water is present at about 10% or 20% by weight. In a specific embodiment, PEG is PEG400 or PEG600. In a specific embodiment, the thiotepa formulation with enhanced stability consists of 10 mg / mL thiotepa, PEG400, and 10% water by weight. In a specific embodiment, the thiotepa formulation with enhanced stability consists of 10 mg / mL thiotepa, PEG 600, and 20% water by weight. In a specific embodiment, the stability-enhanced thiotepa formulation consists of 10 mg / mL thiotepa, DMSO, and 10% by weight water. In another embodiment, the formulation further comprises a thiosulfate.

[0053] Further embodiments include:

[0054] 1. A composition comprising thiotepa, water and an excipient, wherein the excipient is polyethylene glycol (PEG) or dimethyl sulfoxide (DMSO), wherein the thiotepa is present in an amount of about 1 mg / mL to about 100 mg / mL, wherein the water is present in an amount of about up to about 40%, wherein the composition is substantially free of impurities, and wherein the impurities are one or more selected from the group consisting of formic acid, acetic acid, formaldehyde, acetaldehyde and peroxide.

[0055] 2. The composition of paragraph 1, wherein the thiotepa is present in an amount between about 1 mg / mL and about 10 mg / mL.

[0056] 3. The composition described in paragraph 1 or 2, wherein the excipient is PEG400 or PEG600.

[0057] 4. The composition of paragraph 1 or 2, wherein the excipient is DMSO.

[0058] 5. The composition of any of paragraphs 1-4, wherein water is present in an amount selected from the group consisting of up to about 30%, up to about 25%, up to about 20%, up to about 15%, up to about 10%, and up to about 5%.

[0059] 6. The composition of paragraph 5, wherein water is present in an amount up to about 10%.

[0060] 7. The composition of any of paragraphs 1-6, wherein the impurity is present in an amount selected from the group consisting of less than about 35 ppm, less than about 30 ppm, less than about 25 ppm, less than about 20 ppm, less than about 15 ppm, less than about 10 ppm, and less than about 5 ppm.

[0061] 8. The composition of paragraphs 1-7, wherein the impurity is present in an amount selected from the group consisting of about 1 ppm to about 35 ppm, 1 ppm to about 30 ppm, 1 ppm to about 25 ppm, 1 ppm to about 20 ppm, 1 ppm to about 15 ppm, 1 ppm to about 10 ppm, and 1 ppm to about 5 ppm.

[0062] 9. The composition of any of paragraphs 1-8, wherein the impurity is one or more of: less than about 15 ppm formic acid, less than about 15 ppm acetic acid, less than about 15 ppm formaldehyde, less than about 15 ppm acetaldehyde, or less than about 35 ppm peroxide.

[0063] 10. The composition of any of paragraphs 1-8, wherein the impurities are one or more of: less than about 15 ppm formic acid, less than about 15 ppm acetic acid, less than about 15 ppm formaldehyde, less than about 15 ppm acetaldehyde, and less than about 35 ppm peroxide.

[0064] 11. The composition of any of paragraphs 1-10, further comprising a thiosulfate.

[0065] 12. The composition of paragraph 11, wherein the thiosulfate is present in an amount between about 0.01% and about 1.0%.

[0066] 13. The composition of paragraph 11 or 12, wherein the thiosulfate is present in an amount of about 0.1%.

[0067] 14. The composition of paragraph 1, consisting of thiotepa, PEG 400, water, and less than about 10 ppm formic acid, less than about 15 ppm formic acid, less than about 15 ppm acetic acid, less than about 15 ppm formaldehyde, less than about 15 ppm acetaldehyde, and less than about 35 ppm peroxide.

[0068] 15. The composition of paragraph 14, comprising about 10 mg / mL thiotepa and about 10% by weight water.

[0069] 16. The composition of paragraph 1, consisting of thiotepa, PEG600, water, and less than about 15 ppm formic acid, less than about 15 ppm acetic acid, less than about 15 ppm formaldehyde, less than about 15 ppm acetaldehyde, and less than about 35 ppm peroxide.

[0070] 17. The composition of paragraph 16, comprising about 10 mg / mL thiotepa and about 20% by weight water.

[0071] 18. The composition of paragraph 1, consisting of thiotepa, DMSO, water, and less than about 15 ppm formic acid, less than about 15 ppm acetic acid, less than about 15 ppm formaldehyde, less than about 15 ppm acetaldehyde, and less than about 35 ppm peroxide.

[0072] 19. The composition of paragraph 11, comprising about 10 mg / mL thiotepa and about 10% by weight water.

[0073] 20. The composition of any of paragraphs 1-19, further comprising tocopherol.

[0074] 21. The composition of paragraph 1, wherein the excipient is PEG 400 and the composition has a peroxide value of less than about 1.0 mEq O2 / kg fat.

[0075] 22. The composition of paragraph 21, wherein the peroxide value is less than about 0.5 mEq O2 / kg fat.

[0077] 23. An anhydrous composition comprising thiotepa and a solvent, wherein the solvent is selected from the group consisting of dimethyl sulfoxide (DMSO), polyethylene glycol 400 (PEG400), polyethylene glycol 600 (PEG600), dimethylacetamide (DMA) and N-methylpyrrolidone (NMP), and wherein the thiotepa is present in an amount between about 1 mg / mL and about 100 mg / mL, wherein the composition is substantially free of impurities, and wherein the impurities are selected from one or more of the group consisting of formic acid, acetic acid, formaldehyde, acetaldehyde and peroxide.

[0078] 24. The composition of paragraph 23, wherein the impurity is present in an amount selected from the group consisting of less than about 35 ppm, less than about 30 ppm, less than about 25 ppm, less than about 20 ppm, less than about 15 ppm, less than about 10 ppm, and less than about 5 ppm.

[0079] 25. The composition of paragraph 23 or 24, wherein the impurity is present in an amount selected from the group consisting of about 1 to about 35 ppm, 1 to about 30 ppm, 1 to about 25 ppm, 1 to about 20 ppm, 1 to about 15 ppm, 1 to about 10 ppm, and 1 to about 5 ppm.

[0080] 26. The composition of any of paragraphs 23-25, wherein the impurity is one or more of: less than about 15 ppm formic acid, less than about 15 ppm acetic acid, less than about 15 ppm formaldehyde, less than about 15 ppm acetaldehyde, or less than about 35 ppm peroxide.

[0081] 27. The composition of any of paragraphs 23-26, wherein the impurities are one or more of: less than about 15 ppm formic acid, less than about 15 ppm acetic acid, less than about 15 ppm formaldehyde, less than about 15 ppm acetaldehyde, and less than about 35 ppm peroxide.

[0082] 28. The anhydrous composition of any of paragraphs 23-27, further comprising an antioxidant and an organic base.

[0083] 29. The anhydrous composition of any of paragraphs 23-28, wherein the antioxidant is tocopherol.

[0084] 30. The anhydrous composition of any of paragraphs 23-29, wherein the organic base is Tris base.

[0085] 31. A method for treating cancer in a subject in need thereof, the method comprising administering to the subject the composition of any of paragraphs 1-30.

[0086] 32. The method of paragraph 31, wherein the cancer is selected from the group consisting of bladder cancer, malignant meningeal neoplasms, breast cancer, and ovarian cancer.

[0087] 33. The method of paragraph 31 or 32, wherein the composition is administered by injection.

[0088] 34. The method of paragraph 33, wherein the injection is selected from the group consisting of subcutaneous injection, intramuscular injection, intravenous injection, infusion, intraperitoneal injection, intrapleural injection, intrapericardial injection, intrathecal injection, intraarterial injection, intravesical injection and intralesional injection.

[0089] 35. The method of any of paragraphs 31-34, comprising administering between about 300 mg and about 700 mg of thiotepa.

[0090] 36. The method of any of paragraphs 31-35, wherein the thiotepa is stable.

[0091] 37. A method for myeloablation prior to bone marrow transplantation in a subject in need thereof, the method comprising administering to the subject the composition of any of paragraphs 1-30.

[0092] 38. A method for enhancing the stability of a thiotepa formulation, the method comprising: combining thiotepa, water, and a component selected from PEG and DMSO; and homogenizing the combination, wherein the concentration of thiotepa after the homogenization step is between about 1 and about 100 mg / mL, wherein water comprises between about 1% and about 40% by weight of the composition, wherein the composition is substantially free of impurities, and wherein the impurities are one or more selected from the group consisting of formic acid, acetic acid, formaldehyde, acetaldehyde, and peroxide.

[0093] 39. The method of paragraph 38, wherein the concentration of thiotepa is about 10 mg / mL.

[0094] 40. The method of paragraphs 38 or 39, wherein water comprises about 10% or about 20% by weight of the composition.

[0095] 41. The method of any of paragraphs 38-40, wherein the PEG is PEG400 or PEG600.

[0096] 42. The method of any of paragraphs 38-41, wherein the thiotepa formulation consists of 10 mg / mL thiotepa, PEG 400, and 10% by weight water.

[0097] 43. The method of any of paragraphs 38-42, wherein the thiotepa formulation consists of 10 mg / mL thiotepa, PEG600, and 20% by weight water.

[0098] 44. The method of any of paragraphs 38-43, wherein the thiotepa formulation consists of 10 mg / mL thiotepa, DMSO, and 10% water by weight.

[0099] 45. The method of any of paragraphs 38-44, further comprising adding a thiosulfate to the composition.

[0100] 46. ​​The method of paragraph 45, wherein the thiosulfate is between about 0.01% and about 10% by weight.

[0101] 47. The method of paragraph 46, wherein the thiosulfate comprises about 0.1% by weight. Example

[0102] Example 1: Stability of Thiotepa Aqueous Composition

[0103] 100mg thiotepa is weighed into an amber container, and 10mL PEG400, PEG600 or DMSO (as appropriate) is added to the container. Purified water is added to the container at 10% (Example 1, Example 2, Example 5 and Example 6) or 20% (Example 3 and Example 4) by weight. 0.1% thiosulfate / ester (by weight) is added in Example 2, Example 4 and Example 6. The preparation is homogenized and stirred overnight with a magnetic stirrer. The preparation is divided into separate vials and stored at 5°C or 25°C / 60% relative humidity (RH).

[0104] The formulations were assayed by HPLC at 2 weeks, 1.5 months (6 weeks), 3.5 months and 5 months. The relative standard deviation (RSD) was calculated for each sample. Total impurities and chloroethyl impurities were also quantified by HPLC. HPLC was performed on Waters, Xbridgeshield Rp18, 75X4.6 mm, dp=2.5μm, flow rate 1.5mL / min, injection volume 8μL, run time 12min.

[0105] Tables 4 and 5 show the stability of thiotepa formulations at 5°C and 25°C / 60% RH, respectively.

[0106] Table 4: Thiotepa stability at 5°C (RSD is relative standard deviation)

[0107] Table 5: Thiotepa stability at 25°C / 60% RH

[0108] As shown in the table above, PEG and DMSO formulations with 10% or 20% water were stable when stored at 5° C. Formulations containing PEG400 and PEG600 were stable at both 5° C. and 25° C. / 60% RH for up to 5 months. Figure 1 The chromatogram of the thiotepa composition of Example 1 is shown.

[0109] Example 2: Stability of anhydrous thiotepa compositions

[0110] Weigh 100 mg of thiotepa into an amber container and add 10 mL of PEG400, PEG600, DMSO, DMA or NMP (as appropriate) to the container. Some formulations include tocopherol and Tris base. Homogenize the formulation with a magnetic stirrer and stir overnight. Aliquot the formulation into individual vials and store at 5°C or 25°C / 60% RH.

[0111] The formulations were assayed by HPLC at 2 weeks, 1 month and 2 months. The relative standard deviation (RSD) was calculated for each sample. Total impurities and chloroethyl impurities were also quantified by HPLC. HPLC was performed on Waters, Xbridge shield Rp18, 4.6X150mm, dp=3.5μm, flow rate 1.0mL / min, injection volume 20μL.

[0112] Tables 6 and 7 show the stability of thiotepa formulations at 5°C and 25°C / 60% RH, respectively.

[0113] Table 6: Stability of anhydrous thiophene at 5°C

[0114] Table 7: Anhydrous thiophene stability at 25°C / 60% RH

[0115] The description of the above embodiments is provided for the purpose of illustration and description. It is not intended to be exhaustive or to limit the present disclosure. Individual elements or features of a specific embodiment are generally not limited to that specific embodiment, but, where applicable, are interchangeable and can be used in selected embodiments, even if not specifically shown or described. The same may also vary in many aspects. These variations should not be regarded as departing from the present disclosure, and all such modifications should be included within the scope of the present disclosure.

Claims

1. A composition comprising thiotepa, water and an excipient, in, The excipient is polyethylene glycol (PEG) or dimethyl sulfoxide (DMSO), wherein the thiotepa is present in an amount between about 1 mg / mL and about 100 mg / mL, wherein the water is present in an amount of about up to about 40%, wherein the composition is substantially free of impurities, and Wherein, the impurities are one or more selected from the group consisting of formic acid, acetic acid, formaldehyde, acetaldehyde and peroxide.

2. The composition according to claim 1, wherein The thiotepa is present in an amount of about 10 mg / mL.

3. The composition according to claim 1 or 2, wherein The excipient is PEG400 or PEG600.

4. The composition according to any one of claims 1 to 3, wherein The excipient was DMSO.

5. The composition according to any one of claims 1 to 4, wherein The water is present in an amount selected from the group consisting of up to about 30%, up to about 25%, up to about 20%, up to about 15%, up to about 10%, and up to about 5%.

6. The composition according to claim 5, wherein The water is present in an amount up to about 10%.

7. The composition according to any one of claims 1 to 6, wherein The impurity is present in an amount selected from the group consisting of less than about 100 ppm, less than about 35 ppm, less than about 30 ppm, less than about 25 ppm, less than about 20 ppm, less than about 15 ppm, less than about 10 ppm and less than about 5 ppm.

8. The composition according to any one of claims 1 to 7, wherein The impurity is present in an amount selected from the group consisting of about 1 ppm to about 100 ppm, about 1 ppm to about 35 ppm, 1 ppm to about 30 ppm, 1 ppm to about 25 ppm, 1 ppm to about 20 ppm, 1 ppm to about 15 ppm, 1 ppm to about 10 ppm, and 1 ppm to about 5 ppm.

9. The composition according to any one of claims 1 to 8, wherein The impurities are one or more of the following: Less than about 15 ppm formic acid; Less than about 15 ppm acetic acid; Less than about 15 ppm of formaldehyde; Less than about 15 ppm acetaldehyde; or Less than about 35 ppm peroxide.

10. The composition according to claim 9, wherein The composition comprises: Less than about 15 ppm formic acid; Less than about 15 ppm acetic acid; Less than about 15 ppm of formaldehyde; Less than about 15 ppm acetaldehyde; and Less than about 35 ppm of peroxide.

11. The composition according to any one of claims 1 to 10, further comprising a thiosulfate.

12. The composition according to claim 11, wherein The thiosulfate is present in an amount between about 0.01% and about 1.0%.

13. The composition according to claim 11 or 12, wherein The thiosulfate is present in an amount of about 0.1%.

14. The composition according to claim 1, consisting of: Thiotepa, PEG400, water, and Less than about 15 ppm formic acid; Less than about 15 ppm acetic acid; Less than about 15 ppm of formaldehyde; Less than about 15 ppm acetaldehyde; and Less than about 35 ppm of peroxide.

15. The composition of claim 14, comprising about 10 mg / mL thiotepa and about 10% by weight water.

16. The composition according to claim 1, consisting of: Thiotepa, PEG600, water, and Less than about 15 ppm formic acid; Less than about 15 ppm acetic acid; Less than about 15 ppm of formaldehyde; Less than about 15 ppm acetaldehyde; and Less than about 35 ppm of peroxide.

17. The composition of claim 16, comprising about 10 mg / mL thiotepa and about 20% by weight water.

18. The composition according to claim 1, consisting of: Thiotepa, DMSO, water, and Less than about 15 ppm formic acid; Less than about 15 ppm acetic acid; Less than about 15 ppm of formaldehyde; Less than about 15 ppm acetaldehyde; and Less than about 35 ppm of peroxide.

19. The composition of claim 11, comprising about 10 mg / mL thiotepa and about 10% by weight water.

20. The composition of any one of claims 1-19, further comprising tocopherol.

21. The composition according to claim 1, wherein The excipient is PEG400 and the composition has a peroxide value of less than about 1.0 mEq O2 / kg fat.

22. The composition according to claim 21, wherein The peroxide value is less than about 0.5 mEq O2 / kg fat.

23. An anhydrous composition comprising thiotepa and a solvent, in, The solvent is selected from the group consisting of dimethyl sulfoxide (DMSO), polyethylene glycol 400 (PEG400), polyethylene glycol 600 (PEG600), dimethylacetamide (DMA) and N-methylpyrrolidone (NMP), and wherein the thiotepa is present in an amount between about 1 mg / mL and about 100 mg / mL, wherein the composition is substantially free of impurities, and Wherein, the impurities are one or more selected from the group consisting of formic acid, acetic acid, formaldehyde, acetaldehyde and peroxide.

24. The composition according to claim 23, wherein The impurity is present in an amount selected from the group consisting of less than about 35 ppm, less than about 30 ppm, less than about 25 ppm, less than about 20 ppm, less than about 15 ppm, less than about 10 ppm, and less than about 5 ppm.

25. The composition according to claim 23 or 24, wherein The impurity is present in an amount selected from the group consisting of about 1 ppm to about 35 ppm, 1 ppm to about 30 ppm, 1 ppm to about 25 ppm, 1 ppm to about 20 ppm, 1 ppm to about 15 ppm, 1 ppm to about 10 ppm, and 1 ppm to about 5 ppm.

26. A composition according to any one of claims 23 to 25, wherein The impurities are one or more of the following: Less than about 15 ppm formic acid; Less than about 15 ppm acetic acid; Less than about 15 ppm of formaldehyde; Less than about 15 ppm acetaldehyde; or Less than about 35 ppm of peroxide.

27. A composition according to any one of claims 23 to 26, wherein The composition comprises: Less than about 15 ppm formic acid; Less than about 15 ppm acetic acid; Less than about 15 ppm of formaldehyde; Less than about 15 ppm acetaldehyde; and Less than about 35 ppm of peroxide.

28. The anhydrous composition according to any one of claims 23 to 27, further comprising an antioxidant or an organic base.

29. The anhydrous composition according to any one of claims 23 to 28, wherein The antioxidant is tocopherol.

30. The anhydrous composition according to any one of claims 23 to 29, wherein The organic base is Tris base.

31. A method for treating cancer in a subject in need thereof, the method comprising administering to the subject the composition of any one of claims 1-30.

32. The method according to claim 31, wherein: The cancer is selected from the group consisting of bladder cancer, malignant meningeal neoplasms, breast cancer and ovarian cancer.

33. The method according to claim 31 or 32, wherein: The composition is administered by injection.

34. The method of claim 33, wherein: The injection is selected from the group consisting of subcutaneous injection, intramuscular injection, intravenous injection, infusion, intraperitoneal injection, intrapleural injection, intrapericardial injection, intrathecal injection, intraarterial injection, intravesical injection and intralesional injection.

35. The method of any one of claims 31-34, comprising administering between about 300 mg and about 700 mg of thiotepa.

36. The method according to any one of claims 31 to 35, wherein: The thiotepa is stable.

37. A method for myeloablation prior to bone marrow transplantation in a subject in need thereof, the method comprising: The subject is administered the composition of any one of claims 1-30.

38. A method for enhancing the stability of a thiotepa formulation, the method comprising: combining thiotepa, water, and a component selected from PEG and DMSO; and homogenizing the combination, wherein the concentration of thiotepa after the homogenization step is between about 1 mg / mL and about 100 mg / mL, wherein the water accounts for between about 1% and about 40% by weight of the composition, wherein the composition is substantially free of impurities; and Wherein, the impurities are one or more selected from the group consisting of formic acid, acetic acid, formaldehyde, acetaldehyde and peroxide.

39. The method of claim 38, wherein: The thiotepa concentration was about 10 mg / mL.

40. The method according to claim 38 or 39, wherein: The water comprises about 10% or about 20% by weight of the composition.

41. The method according to any one of claims 38 to 40, wherein: The PEG is PEG400 or PEG600.

42. The method according to any one of claims 38 to 41, wherein: The thiotepa formulation consists of 10 mg / mL thiotepa, PEG400, and 10% by weight of water.

43. The method according to any one of claims 38 to 42, wherein: The thiotepa formulation consists of 10 mg / mL thiotepa, PEG600, and 20% by weight of water.

44. The method according to any one of claims 38 to 43, wherein: The thiotepa formulation consisted of 10 mg / mL thiotepa, DMSO, and 10% by weight water.

45. The method of any one of claims 38-44, further comprising adding thiosulfate to the composition.

46. ​​The method of claim 45, wherein: The thiosulfate comprises from about 0.01% to about 10% by weight.

47. The method of claim 46, wherein: The thiosulfate comprises about 0.1% by weight.